Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

Novel ICD Lead for Conduction System Pacing Enters the Arena

1 articles · 1 outlets · spread 0.00

Novel ICD Lead for Conduction System Pacing Enters the Arena
medical research2 d ago

Novel ICD Lead for Conduction System Pacing Enters the Arena

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • MedPage Today·May 1

    Novel ICD Lead for Conduction System Pacing Enters the Arena

    A dedicated bipolar implantable cardioverter-defibrillator (ICD) lead for conduction system pacing (CSP) performed well in a first-in-human multicenter study. Placement of the novel UltiSynq CSP ICD lead, designed for left bundle branch area (LBBA) pacing, met expectations for safety and effectiveness in over 200 patients with indications for novo ICD or cardiac resynchronization therapy defibrillator (CRT-D) implantation, according to researchers led by Robert Schaller, DO, of the Hospital of the University of Pennsylvania in Philadelphia. In these patients, the 3-month major complication-free rate was 97.5% and the primary effectiveness endpoint (a composite of acceptable pacing capture threshold and R-wave sensing amplitude) reached 94.6%, both exceeding preset goals (88% and 80%, respectively). Additionally, lead electrical performance remained stable through 3 months, Schaller told the audience at the Heart Rhythm Society annual meeting held in Chicago. These and other findings from the single-arm, pivotal ASCEND CSP investigational device exemption study were simultaneously published in Heart Rhythm. "These findings support the early safety and performance of a purpose built CSP ICD lead and demonstrate that integration of physiologic pacing into ICD systems can be achieved without compromising defibrillation reliability. Continued follow-up is essential to confirm long-term durability, electrical stability, and extractability. If sustained,

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

MedPage Today

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.